HuidaGene Therapeutics, based in Shanghai, China and Clinton, New Jersey, have reported preliminary data on a novel gene therapy treatment for RPE-65 LCA (Leber congenital… Read More »HuidaGene Therapeutics presents a novel AAV9 RPE-65 treatment for Leber congenital amaurosis at EURETINA Congress in Barcelona.
Merck (NYSE: MRK) has recently announced the completion of the acquisition of Eyebiotech Limited (EyeBio), now becoming a wholly-owned subsidiary of Merck. EyeBio was founded… Read More »Merck (NYSE: MRK) and Eyebiotech Ltd (UK) completes acquisition, following a recent experimental treatment (“Restoret”) for diabetic macular edema (DME).
4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT), based in Emeryville, California, have announced interim 24-week data from their “PRISM” (WET AMD) and “SPECTRA” (DME) phase I/II… Read More »Positive results from 4DMT announce an improvement on BCVA for a dual-transgene treatment for wet AMD and DME.
Kiora Pharmaceuticals (NASDAQ: KPRX) have announced the receipt of Orphan Medicinal Product Designation from the European Medicines Agency (EMA) for the treatment of IRDs, including… Read More »Kioro Pharmaceuticals (NASDAQ: KPRX) has announced Orphan Medicinal Product Designation for KIO-310, for the treatment of non-syndromic rod-dominant retinal dystrophies.
A private biotech company, Beacon Therapeutics, based in London, UK (and Florida and Cambridge, USA), has received an investment of $170M from several funding partners,… Read More »Beacon Therapeutics has announced an investment of $170M for the development of ophthalmic gene therapies.
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), have announced the reintroduction of “Susvimo” (ranibizumab injection) 100 mg/mL for intravitreal use… Read More »Genentech (Roche Group) announce that FDA has approved the introduction of Susimvo (ranibizumab injection, ocular implant) for wet age-related macular degeneration.
Nanoscope Therapeutics Inc., a company based in Bedford, Texas, has provided an update following recent regulatory discussions with the U.S. Food and Drug Administration (“FDA”)… Read More »Nanoscope Therapeutics Inc., provides a commercial update on MCO-010 treatment of retinitis pigmentosa (RP) using optogenetic therapy.
Opus Genetics Inc., a private ocular gene therapy company based in Raleigh, North Carolina, has announced the completion in the first cohort for a Phase… Read More »Opus Genetics Inc., has announced completion of dowsing in first cohort Phase 1/2 trial for “OPGx-LCA5” for the treatment of LCA5 retinal disease.
Ocugen Inc., (NASDAQ:OCGN), an ophthalmic biopharmaceutical company based in Malvern, Pennsylvania, has announced the completion of dosing in their second cohort of its Phase 1/2… Read More »Ocugen Inc completes dosing of a Phase 1/2 study for a modifier gene therapy to treat Stargardt disease.
A study from Johnson & Johnson Innovative Medicine, New Jersey, United States, report that patients with delayed genetic testing may incur significantly higher healthcare costs… Read More »Johnson & Johnson study reports the economic value of early genetic testing in inherited retinal dystrophies diagnosis.
